KR100383305B1 - 프로스타글란딘i₂작용물질로서의나프탈렌유도체 - Google Patents

프로스타글란딘i₂작용물질로서의나프탈렌유도체 Download PDF

Info

Publication number
KR100383305B1
KR100383305B1 KR1019960704963A KR19960704963A KR100383305B1 KR 100383305 B1 KR100383305 B1 KR 100383305B1 KR 1019960704963 A KR1019960704963 A KR 1019960704963A KR 19960704963 A KR19960704963 A KR 19960704963A KR 100383305 B1 KR100383305 B1 KR 100383305B1
Authority
KR
South Korea
Prior art keywords
hydroxy
compound
naphthyl
tetrahydro
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019960704963A
Other languages
English (en)
Korean (ko)
Other versions
KR970701698A (ko
Inventor
기요시 다니구치
마사노부 나가노
고지 핫토리
가즈노리 츠바키
오사무 오키츠
세이이치로 다부치
Original Assignee
후지사와 야꾸힝 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9404734A external-priority patent/GB9404734D0/en
Priority claimed from GB9407036A external-priority patent/GB9407036D0/en
Application filed by 후지사와 야꾸힝 고교 가부시키가이샤 filed Critical 후지사와 야꾸힝 고교 가부시키가이샤
Publication of KR970701698A publication Critical patent/KR970701698A/ko
Application granted granted Critical
Publication of KR100383305B1 publication Critical patent/KR100383305B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/12—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/16—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by esterified hydroxyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Epoxy Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1019960704963A 1994-03-10 1995-03-08 프로스타글란딘i₂작용물질로서의나프탈렌유도체 Expired - Fee Related KR100383305B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9404734A GB9404734D0 (en) 1994-03-10 1994-03-10 Heterocyclic compounds
GB9404734.7 1994-03-10
GB9407036.4 1994-04-08
GB9407036A GB9407036D0 (en) 1994-04-08 1994-04-08 Naphthalene derivatives

Publications (2)

Publication Number Publication Date
KR970701698A KR970701698A (ko) 1997-04-12
KR100383305B1 true KR100383305B1 (ko) 2003-11-01

Family

ID=26304472

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960704963A Expired - Fee Related KR100383305B1 (ko) 1994-03-10 1995-03-08 프로스타글란딘i₂작용물질로서의나프탈렌유도체

Country Status (17)

Country Link
US (2) US5763489A (enExample)
EP (1) EP0749424B1 (enExample)
JP (1) JP3245864B2 (enExample)
KR (1) KR100383305B1 (enExample)
CN (1) CN1057522C (enExample)
AT (1) ATE205479T1 (enExample)
AU (1) AU688871B2 (enExample)
CA (1) CA2185104A1 (enExample)
DE (1) DE69522676T2 (enExample)
DK (1) DK0749424T3 (enExample)
ES (1) ES2160156T3 (enExample)
GR (1) GR3037080T3 (enExample)
HU (1) HU224822B1 (enExample)
PT (1) PT749424E (enExample)
RU (1) RU2155188C2 (enExample)
TW (1) TW282456B (enExample)
WO (1) WO1995024393A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100345943B1 (ko) * 1993-12-20 2002-11-30 후지사와 야꾸힝 고교 가부시키가이샤 4,5-디아릴옥사졸유도체
TW401408B (en) 1995-07-21 2000-08-11 Fujisawa Pharmaceutical Co Heterocyclic compounds having prostaglandin I2 agonism
DE19537548A1 (de) * 1995-10-09 1997-04-10 Merck Patent Gmbh Endothelin-Rezeptor-Antagonisten
DE19604191A1 (de) * 1996-02-06 1997-08-07 Hoechst Schering Agrevo Gmbh 2,4-Diamino-1,3,5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
AUPO713297A0 (en) 1997-06-02 1997-06-26 Fujisawa Pharmaceutical Co., Ltd. Oxazole compound
GB9720270D0 (en) 1997-09-25 1997-11-26 Pharmagene Lab Limited Medicaments for the treatment of migraine
AUPP003297A0 (en) 1997-10-27 1997-11-20 Fujisawa Pharmaceutical Co., Ltd. 4,5-diaryloxazole compounds
AUPP029197A0 (en) 1997-11-10 1997-12-04 Fujisawa Pharmaceutical Co., Ltd. Benzocycloheptene derivatives
AUPP109097A0 (en) 1997-12-22 1998-01-22 Fujisawa Pharmaceutical Co., Ltd. Napthalene derivatives
US6335459B1 (en) 1998-12-23 2002-01-01 Syntex (U.S.A.) Llc Aryl carboxylic acid and aryl tetrazole derivatives as IP receptor modulators
WO2000078350A1 (en) * 1999-06-21 2000-12-28 Fujisawa Pharmaceutical Co., Ltd. Remedies for skin ulcer
US20040127529A1 (en) * 1999-06-21 2004-07-01 Fujisawa Pharmaceutical Co., Ltd. Remedies for skin ulcer
AU2002224032A1 (en) * 2000-11-21 2002-06-03 Fujisawa Pharmaceutical Co. Ltd. Processes for preparation of tetrahydronaphthalene derivatives
CA2444563A1 (en) * 2001-04-18 2002-10-31 Fujisawa Pharmaceutical Co., Ltd. Tissue fibrosis inhibitors
CN100477995C (zh) 2003-05-09 2009-04-15 东丽株式会社 增强剂
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
WO2008072784A1 (en) 2006-12-14 2008-06-19 Astellas Pharma Inc. Polycyclic acid compounds useful as crth2 antagonists and antiallergic agents
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
HRP20141209T2 (hr) 2008-03-18 2016-05-06 Arena Pharmaceuticals, Inc. Modulatori receptora prostaciklina (pgi2) korisni za liječenje poremećaja povezanih s time
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
ES2401691T3 (es) 2008-11-28 2013-04-23 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Derivados de indol y de benzoxacina como moduladores de los receptores metabotrópicos de glutamato
ES2440001T3 (es) 2009-05-12 2014-01-27 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-A]piridina y su uso para el tratamiento o prevención de trastornos neurológicos y psiquiátricos
SG176018A1 (en) 2009-05-12 2011-12-29 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
ES2552455T3 (es) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
CN103298809B (zh) 2010-11-08 2016-08-31 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
IL279202B2 (en) 2014-01-21 2023-09-01 Janssen Pharmaceutica Nv Combinations containing positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic subtype 2 receptor and their use
US10537573B2 (en) 2014-01-21 2020-01-21 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
KR20220119169A (ko) 2017-03-01 2022-08-26 아레나 파마슈티칼스, 인크. Pgi2-수용체 효능제를 포함하는 조성물 및 그의 제조 방법
JP2025506098A (ja) 2022-02-15 2025-03-07 ユナイテッド セラピューティクス コーポレイション 結晶質プロスタサイクリン（ｉｐ）受容体アゴニストおよびその使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0542203A2 (en) * 1991-11-11 1993-05-19 Ono Pharmaceutical Co., Ltd. Fused benzeneoxyacetic acid derivatives as PGl2 receptor agonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1366514A1 (ru) * 1986-01-28 1988-01-15 Днепропетровский химико-технологический институт им.Ф.Э.Дзержинского Способ получени производных N-арил-5-ариламидо-4,6-диметилпиридона-2
DE3837809A1 (de) * 1988-11-08 1990-05-10 Merck Patent Gmbh Tetralinderivate

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0542203A2 (en) * 1991-11-11 1993-05-19 Ono Pharmaceutical Co., Ltd. Fused benzeneoxyacetic acid derivatives as PGl2 receptor agonists

Also Published As

Publication number Publication date
EP0749424A1 (en) 1996-12-27
KR970701698A (ko) 1997-04-12
HK1013289A1 (en) 1999-08-20
ATE205479T1 (de) 2001-09-15
US5763489A (en) 1998-06-09
CN1057522C (zh) 2000-10-18
TW282456B (enExample) 1996-08-01
AU688871B2 (en) 1998-03-19
WO1995024393A1 (en) 1995-09-14
HU224822B1 (en) 2006-02-28
DE69522676T2 (de) 2002-04-18
GR3037080T3 (en) 2002-01-31
ES2160156T3 (es) 2001-11-01
AU1861895A (en) 1995-09-25
DE69522676D1 (de) 2001-10-18
JPH09509958A (ja) 1997-10-07
JP3245864B2 (ja) 2002-01-15
EP0749424B1 (en) 2001-09-12
HUT75226A (en) 1997-04-28
US5863918A (en) 1999-01-26
CA2185104A1 (en) 1995-09-14
RU2155188C2 (ru) 2000-08-27
DK0749424T3 (da) 2001-11-26
PT749424E (pt) 2002-03-28
HU9602466D0 (en) 1996-11-28
CN1147250A (zh) 1997-04-09

Similar Documents

Publication Publication Date Title
KR100383305B1 (ko) 프로스타글란딘i₂작용물질로서의나프탈렌유도체
JP2018012700A (ja) 縮合環類似体の抗線維症剤
PT736018E (pt) Derivados de 4,5-diariloxazol
US8124778B2 (en) Tricyclic inhibitors of fatty acid amide hydrolase
JP2004532229A (ja) 脂肪酸アミド加水分解酵素阻害剤
JP2003137866A (ja) フェニレンジアミン誘導体
JPH0665673B2 (ja) 三環式化合物
EP0458207A2 (en) Indole derivatives
JP2003508396A (ja) プロスタグランジンｉ２（ｐｇｉ２）作動活性を有する４，５−ジアリールオキサゾール化合物
JP3213327B2 (ja) ベンゾチアゾロン誘導体
KR20010041812A (ko) 비트로넥틴 수용체 길항제
US7432392B2 (en) Ester derivatives and medical use thereof
US6448282B1 (en) 1H-4(5)-substituted imidazole derivatives
US6303649B1 (en) Naphthalene derivatives
FR2521992A1 (fr) Nouveaux composes de pyridine utiles comme medicaments
US6384072B1 (en) Benzocycloheptene derivatives
JPH0662547B2 (ja) グリシン誘導体
JP2003522814A (ja) アミノアルコール誘導体
RU2387639C2 (ru) Производные индола, содержащие ацетиленовую группу, в качестве ppar активаторов
HK1013289B (en) Naphthalene derivatives as prostaglandin 12 agonists
JP2008513348A (ja) アミノアルコール誘導体
HUP0004177A2 (hu) 4,5-Diaril-oxazol származékok, a vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
JPH0623170B2 (ja) ビシクロ環系スルホンアミド誘導体およびその製造法
JPWO1997036887A1 (ja) 血小板凝集阻害作用を有する新規ヘテロ環化合物
JP2000001486A (ja) グアニジン誘導体

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20060426

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20060426